Skip to main content

Glucagon-like peptide-1 (GLP-1) receptor agonists


09-23-2019 | Children | EASD 2019 | News

RISE compares alpha, beta cells in youth vs adults with early type 2 diabetes

The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.

09-23-2019 | Liraglutide (T2DM) | EASD 2019 | News

Add-on liraglutide may preserve insulin secretion in type 1 diabetes

Findings from the NewLira trial suggest that addition of the glucagon-like peptide-1 receptor agonist liraglutide to insulin treatment may preserve postprandial insulin secretion among adults with newly diagnosed type 1 diabetes.

09-18-2019 | Semaglutide | EASD 2019 | News

Semaglutide tops liraglutide in SUSTAIN 10

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

09-18-2019 | Semaglutide | EASD 2019 | News

SUSTAIN 8: Semaglutide outperforms canagliflozin as second-line therapy for type 2 diabetes

Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.

09-17-2019 | Semaglutide | EASD 2019 | News

PIONEER data support oral semaglutide across a wide range of patients

Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.

08-19-2019 | GLP-1 agonists | Highlight | News

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

08-09-2019 | Insulin | News

Weight loss differences seen with fixed vs flexible insulin, GLP-1RA regimens

Patients initiating a flexible combination of basal insulin plus a glucagon-like peptide-1 receptor agonist have similar improvements in glycemic control to those initiating a fixed combination, but with greater weight loss, real-world study data show.

07-15-2019 | Medications | News

Second-line type 2 diabetes therapies vary globally

Second-line therapy choices for people with type 2 diabetes vary widely throughout the world and are influenced not only by clinical characteristics but also non-medical factors such as affordability and availability, results from the DISCOVER study show.

06-11-2019 | Semaglutide | ADA 2019 | News

Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6

The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.

06-10-2019 | Dulaglutide | ADA 2019 | News

Dulaglutide cardioprotective in relatively low-risk REWIND population

The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.

06-10-2019 | Prediabetes | ADA 2019 | News

RISE adult medication results highlight disparity with youth with diabetes

Intensive antidiabetic treatment in adults with newly diagnosed type 2 diabetes slows the decline in beta-cell function, but this is not sustained after the treatment is stopped, show the results of the RISE adult medication study.

06-10-2019 | Semaglutide | ADA 2019 | News

PIONEER 8: Semaglutide add-on lowers HbA1c in type 2 diabetes insulin users

Oral semaglutide significantly reduces glycated hemoglobin and bodyweight versus placebo in people with type 2 diabetes that is poorly controlled on insulin, results of the PIONEER 8 study show.

06-09-2019 | SGLT2 inhibitors | ADA 2019 | News

SGLT2 inhibitor, GLP-1 receptor agonist risk–benefits explored in older adults

Older people starting treatment with sodium-glucose cotransporter 2 inhibitors have a lower risk for hospitalization for heart failure than those starting glucagon-like peptide-1 receptor agonists, research shows.

06-09-2019 | Semaglutide | ADA 2019 | News

PIONEER trials test oral semaglutide in moderate renal impairment, flexible dosing

The PIONEER 5 and 7 trials show the efficacy of oral semaglutide in people with moderate renal impairment and the potential for a flexible dosing regimen.

06-09-2019 | Semaglutide | ADA 2019 | News

PIONEER 2, PIONEER 4 show benefits of oral semaglutide in type 2 diabetes

Data from the phase IIIa PIONEER 2 and PIONEER 4 studies show that semaglutide equals or betters both empagliflozin and liraglutide for the reduction of glycated hemoglobin in patients with type 2 diabetes uncontrolled on metformin.

06-06-2019 | Liraglutide (T2DM) | News

Liraglutide may be an option for people with unresolved type 2 diabetes after metabolic surgery

Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.

04-29-2019 | Liraglutide (T2DM) | Highlight | News

Ellipse trial: Liraglutide expands treatment options for pediatric type 2 diabetes

The Ellipse investigators report improved glycemic control at the price of early and mostly mild gastrointestinal events in children and adolescents with type 2 diabetes.

03-26-2019 | Semaglutide | Highlight | News

PIONEER 3: Oral semaglutide proves worth against sitagliptin

Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.

03-14-2019 | Hypoglycemia | News

Real-world hypoglycemia data support continued sulfonylurea role in type 2 diabetes

Hypoglycemia is common among people being treated for type 2 diabetes, particularly those using insulin or a sulfonylurea, but the risk for severe episodes is only elevated among insulin users, suggest results of a prospective UK study.

03-05-2019 | Semaglutide | News

SUSTAIN 9 supports semaglutide, SGLT2 inhibitor combination

Adding the glucagon-like peptide-1 analog semaglutide to an existing sodium-glucose cotransporter 2 inhibitor improves glycemic control and bodyweight in patients with poorly controlled type 2 diabetes, SUSTAIN 9 data show.

Image Credits